Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi
Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 majo...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical pathology 2003-04, Vol.119 (4), p.587-593 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 593 |
|---|---|
| container_issue | 4 |
| container_start_page | 587 |
| container_title | American journal of clinical pathology |
| container_volume | 119 |
| creator | TOUAB, Malika ARUMI-URIA, Montserrat BARRANCO, Cargos BASSOLS, Anna |
| description | Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 major proteoglycans expressed by malignant melanoma, and they have a role in the regulation of cell adhesion, migration, and differentiation. We evaluated the differences in versican and mel-CSPG expression in nevi, NAD with several degrees of atypia, and primary malignant melanoma. Immunoreactivity for versican was negative in benign melanocytic nevi, positive in NAD (ranging from weakly to intensely positive), and intensely positive in malignant melanoma. Immunostaining for mel-CSPG was negative in benign melanocytic nevi and mild to moderately positive in NAD and melanoma. Our results suggest that versican expression may be of value for distinguishing NAD from benign melanocytic nevi and for distinguishing severe NAD from mild and moderate NAD. |
| doi_str_mv | 10.1309/ME25J1G5ENE57LM3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73208418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73208418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3523-8b2ccd74ed6e3536a3e354598590b3631c12c0cd08aa000af00b0e7d951e77223</originalsourceid><addsrcrecordid>eNpdkL1PwzAUxC0EoqWwMyEvsAWe7ThORlSFFtQCEjBHjvMCRvkodlrR_55UjVSJ6d7wu9O9I-SSwS0TkNwtUy6f2Eymz6lUi6U4ImOWhCJQivNjMgYAHiRMiRE58_4bgPEYwlMyYlwxYIKNyTz9XTn03rYNbUvafSFdubbD9rPaGt14ukHnbX9R3RS0xiqYvr3OqG1osfWrSvvOGtrgxp6Tk1JXHi8GnZCPh_R9Og8WL7PH6f0iMEJyEcQ5N6ZQIRYRCikiLXoJZRLLBHIRCWYYN2AKiLXu6-sSIAdURSIZ7r4SE3Kzz-1r_qzRd1ltvcGq0g22a58pwSEOWdyDsAeNa713WGYrZ2vtthmDbLde9n-93nI1ZK_zGouDYZirB64HQHujq9Lpxlh_4MIokjyJxR9xqXa6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73208418</pqid></control><display><type>article</type><title>Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>TOUAB, Malika ; ARUMI-URIA, Montserrat ; BARRANCO, Cargos ; BASSOLS, Anna</creator><creatorcontrib>TOUAB, Malika ; ARUMI-URIA, Montserrat ; BARRANCO, Cargos ; BASSOLS, Anna</creatorcontrib><description>Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 major proteoglycans expressed by malignant melanoma, and they have a role in the regulation of cell adhesion, migration, and differentiation. We evaluated the differences in versican and mel-CSPG expression in nevi, NAD with several degrees of atypia, and primary malignant melanoma. Immunoreactivity for versican was negative in benign melanocytic nevi, positive in NAD (ranging from weakly to intensely positive), and intensely positive in malignant melanoma. Immunostaining for mel-CSPG was negative in benign melanocytic nevi and mild to moderately positive in NAD and melanoma. Our results suggest that versican expression may be of value for distinguishing NAD from benign melanocytic nevi and for distinguishing severe NAD from mild and moderate NAD.</description><identifier>ISSN: 0002-9173</identifier><identifier>EISSN: 1943-7722</identifier><identifier>DOI: 10.1309/ME25J1G5ENE57LM3</identifier><identifier>PMID: 12710131</identifier><identifier>CODEN: AJCPAI</identifier><language>eng</language><publisher>Chicago, IL: American Society of Clinical Pathologists</publisher><subject>Aggrecans ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Chondroitin Sulfate Proteoglycans - metabolism ; Dermatology ; Dysplastic Nevus Syndrome - metabolism ; Dysplastic Nevus Syndrome - pathology ; Extracellular Matrix Proteins ; Glycoproteins - metabolism ; Humans ; Immunoenzyme Techniques ; Lectins, C-Type ; Medical sciences ; Melanocytes - metabolism ; Melanocytes - pathology ; Melanoma - metabolism ; Melanoma - pathology ; Neoplasm Proteins - metabolism ; Proteoglycans - metabolism ; Skin Neoplasms - metabolism ; Skin Neoplasms - pathology ; Tumors of the skin and soft tissue. Premalignant lesions ; Versicans</subject><ispartof>American journal of clinical pathology, 2003-04, Vol.119 (4), p.587-593</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3523-8b2ccd74ed6e3536a3e354598590b3631c12c0cd08aa000af00b0e7d951e77223</citedby><cites>FETCH-LOGICAL-c3523-8b2ccd74ed6e3536a3e354598590b3631c12c0cd08aa000af00b0e7d951e77223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14665298$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12710131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TOUAB, Malika</creatorcontrib><creatorcontrib>ARUMI-URIA, Montserrat</creatorcontrib><creatorcontrib>BARRANCO, Cargos</creatorcontrib><creatorcontrib>BASSOLS, Anna</creatorcontrib><title>Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi</title><title>American journal of clinical pathology</title><addtitle>Am J Clin Pathol</addtitle><description>Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 major proteoglycans expressed by malignant melanoma, and they have a role in the regulation of cell adhesion, migration, and differentiation. We evaluated the differences in versican and mel-CSPG expression in nevi, NAD with several degrees of atypia, and primary malignant melanoma. Immunoreactivity for versican was negative in benign melanocytic nevi, positive in NAD (ranging from weakly to intensely positive), and intensely positive in malignant melanoma. Immunostaining for mel-CSPG was negative in benign melanocytic nevi and mild to moderately positive in NAD and melanoma. Our results suggest that versican expression may be of value for distinguishing NAD from benign melanocytic nevi and for distinguishing severe NAD from mild and moderate NAD.</description><subject>Aggrecans</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Chondroitin Sulfate Proteoglycans - metabolism</subject><subject>Dermatology</subject><subject>Dysplastic Nevus Syndrome - metabolism</subject><subject>Dysplastic Nevus Syndrome - pathology</subject><subject>Extracellular Matrix Proteins</subject><subject>Glycoproteins - metabolism</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Lectins, C-Type</subject><subject>Medical sciences</subject><subject>Melanocytes - metabolism</subject><subject>Melanocytes - pathology</subject><subject>Melanoma - metabolism</subject><subject>Melanoma - pathology</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Proteoglycans - metabolism</subject><subject>Skin Neoplasms - metabolism</subject><subject>Skin Neoplasms - pathology</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>Versicans</subject><issn>0002-9173</issn><issn>1943-7722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkL1PwzAUxC0EoqWwMyEvsAWe7ThORlSFFtQCEjBHjvMCRvkodlrR_55UjVSJ6d7wu9O9I-SSwS0TkNwtUy6f2Eymz6lUi6U4ImOWhCJQivNjMgYAHiRMiRE58_4bgPEYwlMyYlwxYIKNyTz9XTn03rYNbUvafSFdubbD9rPaGt14ukHnbX9R3RS0xiqYvr3OqG1osfWrSvvOGtrgxp6Tk1JXHi8GnZCPh_R9Og8WL7PH6f0iMEJyEcQ5N6ZQIRYRCikiLXoJZRLLBHIRCWYYN2AKiLXu6-sSIAdURSIZ7r4SE3Kzz-1r_qzRd1ltvcGq0g22a58pwSEOWdyDsAeNa713WGYrZ2vtthmDbLde9n-93nI1ZK_zGouDYZirB64HQHujq9Lpxlh_4MIokjyJxR9xqXa6</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>TOUAB, Malika</creator><creator>ARUMI-URIA, Montserrat</creator><creator>BARRANCO, Cargos</creator><creator>BASSOLS, Anna</creator><general>American Society of Clinical Pathologists</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030401</creationdate><title>Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi</title><author>TOUAB, Malika ; ARUMI-URIA, Montserrat ; BARRANCO, Cargos ; BASSOLS, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3523-8b2ccd74ed6e3536a3e354598590b3631c12c0cd08aa000af00b0e7d951e77223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aggrecans</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Chondroitin Sulfate Proteoglycans - metabolism</topic><topic>Dermatology</topic><topic>Dysplastic Nevus Syndrome - metabolism</topic><topic>Dysplastic Nevus Syndrome - pathology</topic><topic>Extracellular Matrix Proteins</topic><topic>Glycoproteins - metabolism</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Lectins, C-Type</topic><topic>Medical sciences</topic><topic>Melanocytes - metabolism</topic><topic>Melanocytes - pathology</topic><topic>Melanoma - metabolism</topic><topic>Melanoma - pathology</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Proteoglycans - metabolism</topic><topic>Skin Neoplasms - metabolism</topic><topic>Skin Neoplasms - pathology</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>Versicans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TOUAB, Malika</creatorcontrib><creatorcontrib>ARUMI-URIA, Montserrat</creatorcontrib><creatorcontrib>BARRANCO, Cargos</creatorcontrib><creatorcontrib>BASSOLS, Anna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TOUAB, Malika</au><au>ARUMI-URIA, Montserrat</au><au>BARRANCO, Cargos</au><au>BASSOLS, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi</atitle><jtitle>American journal of clinical pathology</jtitle><addtitle>Am J Clin Pathol</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>119</volume><issue>4</issue><spage>587</spage><epage>593</epage><pages>587-593</pages><issn>0002-9173</issn><eissn>1943-7722</eissn><coden>AJCPAI</coden><abstract>Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 major proteoglycans expressed by malignant melanoma, and they have a role in the regulation of cell adhesion, migration, and differentiation. We evaluated the differences in versican and mel-CSPG expression in nevi, NAD with several degrees of atypia, and primary malignant melanoma. Immunoreactivity for versican was negative in benign melanocytic nevi, positive in NAD (ranging from weakly to intensely positive), and intensely positive in malignant melanoma. Immunostaining for mel-CSPG was negative in benign melanocytic nevi and mild to moderately positive in NAD and melanoma. Our results suggest that versican expression may be of value for distinguishing NAD from benign melanocytic nevi and for distinguishing severe NAD from mild and moderate NAD.</abstract><cop>Chicago, IL</cop><pub>American Society of Clinical Pathologists</pub><pmid>12710131</pmid><doi>10.1309/ME25J1G5ENE57LM3</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9173 |
| ispartof | American journal of clinical pathology, 2003-04, Vol.119 (4), p.587-593 |
| issn | 0002-9173 1943-7722 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73208418 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Aggrecans Biological and medical sciences Biomarkers, Tumor - metabolism Chondroitin Sulfate Proteoglycans - metabolism Dermatology Dysplastic Nevus Syndrome - metabolism Dysplastic Nevus Syndrome - pathology Extracellular Matrix Proteins Glycoproteins - metabolism Humans Immunoenzyme Techniques Lectins, C-Type Medical sciences Melanocytes - metabolism Melanocytes - pathology Melanoma - metabolism Melanoma - pathology Neoplasm Proteins - metabolism Proteoglycans - metabolism Skin Neoplasms - metabolism Skin Neoplasms - pathology Tumors of the skin and soft tissue. Premalignant lesions Versicans |
| title | Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T16%3A10%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20the%20proteoglycans%20versican%20and%20mel-CSPG%20in%20dysplastic%20nevi&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=TOUAB,%20Malika&rft.date=2003-04-01&rft.volume=119&rft.issue=4&rft.spage=587&rft.epage=593&rft.pages=587-593&rft.issn=0002-9173&rft.eissn=1943-7722&rft.coden=AJCPAI&rft_id=info:doi/10.1309/ME25J1G5ENE57LM3&rft_dat=%3Cproquest_cross%3E73208418%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73208418&rft_id=info:pmid/12710131&rfr_iscdi=true |